News

Since the initiative was announced in January 2018, more than 120 health organizations representing about a third of the nation’s hospitals have contacted Civica Rx and expressed a

Filgotinib, an investigational and selective JAK1 inhibitor, has achieved its primary efficacy endpoint in adults with moderately to severely active AS in the phase 2 Tortuga study. AS

Imprime PGG is an innate immune trigger that activates anti-cancer T cells.  Durvalumab is a human monocolonal antibody that blocks the immune checkpoint protein, programmed death-ligand (PD-L1), and

Proceeds from the financing will be used to advance Fulcrum’s lead program in facioscapulohumeral muscular dystrophy (FSHD) into clinical testing, and to progress its pipeline of therapeutics for

Under the agreement, Aurobindo will purchase Sandoz US dermatology business and generic US oral solids portfolio. As part of the deal, Aurobindo will acquire manufacturing facilities in Wilson

Scientists will work in the Boehringer Ingelheim-Tsinghua University Joint Research Center for Immuno-Infection to harness the mechanisms of immune modulation to combat infectious diseases. The collaboration brings together

Redx will now work with the investigators to finalize this protocol, with the intention of restarting dosing of patients in the first half of 2019. Based on a

Merkel cell carcinoma is a rare form of skin cancer caused by a Merkel cell associated polyomavirus. The company’s supplemental biologics license application (sBLA), which has been accepted

Over this period, CHDI may fund up to 75 full-time scientists at Evotec. The collaboration was initiated in 2006 and has grown considerably over this period to fully